A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
58
Samsung Medical Center
Seoul, South Korea
Annualized height velocity(cm/year) after 52 weeks
Height velocity calculated with height measured at Baseline and after 52 weeks was converted to annual growth rate
Time frame: 52 weeks
Changes in height standard deviation score after 52 weeks
Time frame: 52 weeks
Changes in bone maturation(changes in bone ages/changes in chronological age)
Time frame: 52 weeks
Changes in IGF-1
Time frame: 52 weeks
Changes in IGFBP-3
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.